Recently, CXL increased as a treatment strategy for progressive keratoconus. The growing number of clinical reports suggest not only a consistent stabilizing effect of CXL, but also a variable ...
Keratoconus is a noninflammatory, progressive, bilateral ectatic corneal disease with corneal stromal thinning that results in weakening and surface distortion of the cornea. The onset of this disease ...
Please provide your email address to receive an email when new articles are posted on . Despite all our advances, keratoconus remains a major cause of visual disability, even in the developed world.
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a ...
New research led by scientists at Newcastle University, UK reveals a potential revolutionary way to treat eye injuries and prevent blindness—by softening the tissue hosting the stem cells which then ...
Two surgical procedures have been described for ICRS implantation: the mechanical method and the femtolaser method. The use of femtolaser for ICRS tunnel creation was widely accepted after FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results